Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Aberrantly expressed CEACAM6 is involved in the signaling leading to apoptosis of acute lymphoblastic leukemia cells

V. Kanderová, O. Hrusák, T. Kalina,

. 2010 ; 38 (8) : 653-660.e1. [pub] 20100407

Language English Country Netherlands

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
NS10473 MZ0 CEP Register

OBJECTIVE: The aberrant expression of myeloid antigens on acute lymphoblastic leukemia (ALL) cells is a well-documented phenomenon. So far, there have been no reports of a functional consequence of this aberrant expression. The granulocytic marker carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6, CD66c) is a GPI-anchored molecule that is reported to be the most frequently aberrantly expressed myeloid marker in ALL with a strong correlation with genotype. MATERIALS AND METHODS: We mimicked CEACAM6 signaling in ALL cells by cross-linking with anti-CEACAM6 antibody. Next, we measured a response to CEACAM6 signaling by integrin subunits expression, integrin ligand binding, phosphorylation of extracellular signal-regulated kinase 1/2 (Erk1/2), Akt, and p38 mitogen-activated protein kinase (MAPK) and apoptosis by flow cytometry. RESULTS: Following CEACAM6 cross-linking in ALL cells, we detected Erk1/2, Akt, and p38 MAPK phosphorylation and integrin upregulation, as well as enhanced binding of integrin ligands (vascular cell adhesion molecule-1 [VCAM-1] and intercellular cell adhesion molecule-1 [ICAM-1]). However, CEACAM6 signaling resulted in an increase in apoptosis, unlike other GPI-anchored molecules, such as CD24. CONCLUSION: The present study is the first to demonstrate the functional consequences of CEACAM6 cross-linking in B-cell precursor ALL cells.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12025800
003      
CZ-PrNML
005      
20141014095843.0
007      
ta
008      
120817e20100407ne f 000 0#eng||
009      
AR
024    7_
$a 10.1016/j.exphem.2010.03.018 $2 doi
035    __
$a (PubMed)20380867
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Kanderová, Veronika $u Department of Pediatric Hematology and Oncology, Charles University Prague, University Hospital Motol, Czech Republic.
245    10
$a Aberrantly expressed CEACAM6 is involved in the signaling leading to apoptosis of acute lymphoblastic leukemia cells / $c V. Kanderová, O. Hrusák, T. Kalina,
520    9_
$a OBJECTIVE: The aberrant expression of myeloid antigens on acute lymphoblastic leukemia (ALL) cells is a well-documented phenomenon. So far, there have been no reports of a functional consequence of this aberrant expression. The granulocytic marker carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6, CD66c) is a GPI-anchored molecule that is reported to be the most frequently aberrantly expressed myeloid marker in ALL with a strong correlation with genotype. MATERIALS AND METHODS: We mimicked CEACAM6 signaling in ALL cells by cross-linking with anti-CEACAM6 antibody. Next, we measured a response to CEACAM6 signaling by integrin subunits expression, integrin ligand binding, phosphorylation of extracellular signal-regulated kinase 1/2 (Erk1/2), Akt, and p38 mitogen-activated protein kinase (MAPK) and apoptosis by flow cytometry. RESULTS: Following CEACAM6 cross-linking in ALL cells, we detected Erk1/2, Akt, and p38 MAPK phosphorylation and integrin upregulation, as well as enhanced binding of integrin ligands (vascular cell adhesion molecule-1 [VCAM-1] and intercellular cell adhesion molecule-1 [ICAM-1]). However, CEACAM6 signaling resulted in an increase in apoptosis, unlike other GPI-anchored molecules, such as CD24. CONCLUSION: The present study is the first to demonstrate the functional consequences of CEACAM6 cross-linking in B-cell precursor ALL cells.
650    _2
$a protilátky nádorové $x imunologie $x farmakologie $7 D000912
650    _2
$a CD antigeny $x imunologie $x metabolismus $7 D015703
650    _2
$a antigeny nádorové $x imunologie $x metabolismus $7 D000951
650    _2
$a apoptóza $7 D017209
650    _2
$a molekuly buněčné adheze $x antagonisté a inhibitory $x imunologie $x metabolismus $7 D015815
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a GPI-vázané proteiny $7 D058851
650    _2
$a regulace genové exprese u leukemie $7 D015973
650    _2
$a lidé $7 D006801
650    _2
$a imunologický capping $7 D007152
650    _2
$a integriny $x imunologie $x metabolismus $7 D016023
650    _2
$a mezibuněčná adhezivní molekula-1 $x imunologie $x metabolismus $7 D018799
650    _2
$a MAP kinasový signální systém $7 D020935
650    _2
$a mitogenem aktivovaná proteinkinasa 3 $x imunologie $x metabolismus $7 D048052
650    _2
$a onkogenní protein v-akt $x imunologie $x metabolismus $7 D051058
650    _2
$a fosforylace $x účinky léků $x imunologie $7 D010766
650    _2
$a pre-B-buněčná leukemie $x imunologie $x metabolismus $7 D015452
650    _2
$a mitogenem aktivované proteinkinasy p38 $x imunologie $x metabolismus $7 D048051
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hrusák, Ondrej
700    1_
$a Kalina, Tomás
773    0_
$w MED00001746 $t Experimental hematology $x 1873-2399 $g Roč. 38, č. 8 (20100407), s. 653-660.e1
856    41
$u https://pubmed.ncbi.nlm.nih.gov/20380867 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120817 $b ABA008
991    __
$a 20141014100236 $b ABA008
999    __
$a ok $b bmc $g 947842 $s 783146
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 38 $c 8 $d 653-660.e1 $e 20100407 $i 1873-2399 $m Experimental hematology $n Exp Hematol $x MED00001746
GRA    __
$a NS10473 $p MZ0
LZP    __
$a Pubmed-20120817/10/03

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...